Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL6 | P41182 | 1/20 | 0.56 |
| ▸ | CTSC | P53634 | 9/20 | 0.52 |
| ▸ | SYK | P43405 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | JAK3 | P52333 | 1/20 | 0.46 |
| ▸ | SIRT7 | Q9NRC8 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 3/20 | 0.46 |
| ▸ | AHR | P35869 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1025450 | 0.89 | BCL6 (0.49) | BCL6CTSCSYKKDM4EMEN1 | |
| SCHEMBL1026771 | 0.87 | CTSC (0.47) | BCL6CTSCSYKJAK2JAK1 | |
| SCHEMBL1073861 | 0.86 | MAP3K8 (0.46) | BCL6CTSCSYKEGFRABL1 | |
| SCHEMBL9923767 | 0.85 | SYK (0.51) | SYKKDM4EMEN1LMNAGAA | |
| SCHEMBL4175837 | 0.85 | SYK (0.51) | SYKKDM4EMEN1LMNAGAA | |
| SCHEMBL10447761 | 0.85 | SYK (0.56) | BCL6CTSCSYKKDM4EMEN1 | |
| SCHEMBL656259 | 0.85 | SYK (0.72) | BCL6SYKKDM4EMEN1LMNA | |
| SCHEMBL1025860 | 0.84 | CTSC (0.48) | BCL6CTSCSYKJAK2JAK1 | |
| SCHEMBL13623083 | 0.84 | BCL6 (0.44) | BCL6CTSCSYKJAK2JAK1 | |
| SCHEMBL9945497 | 0.83 | EGFR (0.64) | BCL6CTSCKDM4ELMNAJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220218704-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2022-07-14 | — | — | US | disclosed |
| US-20200276194-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2020-09-03 | — | — | US | disclosed |
| US-10434101-B2 | Heterocyclic compounds and uses thereof | CELGENE CAR LLC (BM) | 2019-10-08 | — | — | US | disclosed |
| US-9867824-B2 | Heterocyclic compounds and uses thereof | CELGENE CAR LLC (BM) | 2018-01-16 | — | — | US | disclosed |
| US-9867824-B2 | Heterocyclic compounds and uses thereof | CELGENE CAR LLC (BM) | 2018-01-16 | — | — | US | disclosed |
| US-20170027937-A1 | Heterocyclic Compounds and Uses Thereof | BRISTOL-MYERS SQUIBB COMPANY | 2017-02-02 | — | — | US | disclosed |
| US-20170027937-A1 | Heterocyclic Compounds and Uses Thereof | BRISTOL-MYERS SQUIBB COMPANY | 2017-02-02 | — | — | US | disclosed |
| US-9375431-B2 | 2,4-disubstituted pyrimidine compounds useful as kinase inhibtors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-9375431-B2 | 2,4-disubstituted pyrimidine compounds useful as kinase inhibtors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-20150246040-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2015-09-03 | — | — | US | disclosed |
| US-20150246040-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2015-09-03 | — | — | US | disclosed |
| US-8975249-B2 | Heterocyclic compounds and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-8975249-B2 | Heterocyclic compounds and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-20120149687-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149687-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| WO-2012061299-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10434101-B2 | Heterocyclic compounds and uses thereof | ABCG2, CYP3A5, CYP3A43 | BCL6 2629/4885CTSC 482/4885SYK 2551/4885 |
| US-20170027937-A1 | Heterocyclic Compounds and Uses Thereof | ABCG2, CYP3A5, CYP3A43 | BCL6 2629/4885CTSC 482/4885SYK 2551/4885 |
| US-20220218704-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ABCG2, CYP3A5, CYP3A43 | BCL6 2629/4885CTSC 482/4885SYK 2551/4885 |
| US-20200276194-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ABCG2, CYP3A5, CYP3A43 | BCL6 2629/4885CTSC 482/4885SYK 2551/4885 |
| US-20150246040-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ABCG2, CYP3A5, CYP3A43 | BCL6 2629/4885CTSC 482/4885SYK 2551/4885 |
| US-20120149687-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ABCG2, CYP3A5, CYP3A43 | BCL6 2629/4885CTSC 482/4885SYK 2551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.